echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Ascent Pharma's original Class 1 new drug APG-115 for the treatment of hematological tumors in a phase Ib clinical study completed the first patient administration in China

    Ascent Pharma's original Class 1 new drug APG-115 for the treatment of hematological tumors in a phase Ib clinical study completed the first patient administration in China

    • Last Update: 2020-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Introduction: AML is a cloned proliferative disease of bone marrow, the most common leukemia in China, about 1.62 to 2.32 people / 100,000 people.
    Axa Pharma announced today that the company has completed the first phase Ib clinical study of a new class 1 drug MDM2-p53 inhibitor APG-115 as a single drug and a combination of treatments for adult recurrence or difficult treatment of acute myeloid leukemia (AML), recurrence or progression of high-risk/extremely high-risk bone marrow hyperplasia syndrome (MDS), and has completed the first patient administration in China.
    as the first MDM2-p53 inhibitor to enter clinical phase in China for the treatment of solid tumors, this is the first clinical study of APG-115 to engage in blood tumor indications.
    the study as a national multicenter Ib clinical study designed to assess the safety, pharmacokinetics, and pharmacodynamics characteristics of patients with blood tumors such as APG-115 as a single and aarnucleocosine or aglycosine treatment for recurrence or difficult treatment of AML, recurrence or progression of high-risk/extremely high-risk MDS.
    AML is a cloned proliferative disease of bone marrow, the incidence increases with age, is the most common leukemia in China, about 1.62 to 2.32 people / 100,000 people.
    treatment for AML has been based on a "7-plus-three" combination (7-day glycosine plus 3-day cycloidal drugs) as the standard induction therapy, but up to 40% of newly diagnosed AML patients are still unable to achieve full remission (CR), i.e. incurable, or relapse within 6 months of obtaining CR.
    MDS is a group of heterogeneous hematopoietic diseases derived from abnormally pluripotent stem cells, characterized by low hematopoietic function, bone marrow failure, reduction of peripheral blood cells and decreased survival rate.
    in China, the incidence of MDS is about 5 per 100,000 people.
    demethylation drugs have a high response rate for Treatment of MDS, many patients end up developing resistance to the effects of demethylated drugs.
    once drug resistance occurs, the overall prognosis becomes very poor.
    in high-risk MDS patients, the failure of demethylation drugs was associated with an average survival of less than 6 months.
    so there is an urgent need for new treatments and more effective treatments for AML or MDS patients with relapse progression.
    APG-115 is an oral bioavailable, highly selective small molecule MDM2 inhibitor in The Pharmaceuticals of Axa, which has a high binding affinity for MDM2 and restores p53 tumor inhibition by blocking MDM2-p53 interactions.
    APG-115 has previously conducted a number of clinical studies in China and the United States to treat solid tumors, and is the first MDM2-p53 inhibitor to enter a clinical phase in China.
    is currently working on the global clinical development of a number of APG-115 blood tumor indications. "There is still a large and unmet clinical need for the treatment of blood tumors such as AML and MDS, " said Dr. Yifan Yin Yifan, Chief Medical Officer of
    Axa.
    we also note that the development of drugs targeting MDM2-p53 is receiving increasing attention from the industry. As
    the first MDM2-p53 inhibitor to enter clinical phase in China, aPG-115 has shown good safety and initial efficacy in clinical studies on solid tumors.
    we will further explore the potential of APG-115 in blood tumors to provide more treatment options for AML and MDS patients in China and around the world.
    " References s1 ChangR, WuS, ChenW, etal. Analysisondresofleukemia Gansu Province from 2003to 2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ModernMarchMed.2014; 41 (21): 3841-04.[2] TholF, Schlenk RF, Heuser M, Ganser A.2015.HowItreatrefractoryanderelaps edacutemyeloidle.Blood126:319-27 GorebetT, SSD, EsterniB, Gardin C, Itzykson R, etal.2011.Outcomeofhigh-riskmyelodysafter plastic syndrome Azacitidinetreatmentfailure.JClin Oncol29:3322-7.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.